Key result
Once-daily telmisartan 40- for 24 weeks achieved target blood pressure in 69.6% of patients and reduced left ventricular mass index from 151.6 to 135.1 g/m2.
Why the study?
Does telmisartan reduce blood pressure and left ventricular mass index in patients with mild-to-moderate hypertension and left ventricular hypertrophy?
Does telmisartan reduce blood pressure and left ventricular mass index in patients with mild-to-moderate hypertension and left ventricular hypertrophy?
Telmisartan effectively reduces blood pressure and induces regression of left ventricular hypertrophy in patients with mild-to-moderate hypertension.
Answers are grounded in this paper and cite their sources.
May support telmisartan for BP control with LVH regression; hypothesis-generating and requires RCTs before practice change.
In this open-label, non-comparative study, the anti-hypertensive efficacy and effect on left ventricular hypertrophy (LVH) of 24 weeks' treatment with once-daily telmisartan 40-80 mg was evaluated in 24 patients with mild-to-moderate hypertension and LVH. Patients were titrated to the higher dose of study drug at week 4 if they did not achieve blood pressure normalization (i.e. systolic blood pressure [SBP]/diastolic blood pressure [DBP] remained > or = 140/90 mmHg). The anti-hypertensive action of telmisartan was assessed using clinic cuff measurements and 24-h ambulatory blood pressure monitoring, and left ventricular mass index (LVMI) was determined by two-dimensional echocardiography at baseline and after 24 weeks of therapy. Telmisartan significantly reduced mean 24-h, daytime and night-time SBP and DBP compared with baseline after 12 and 24 weeks of therapy. Target blood pressure levels, defined as SBP/DBP < 140/90 mm Hg, were achieved in 16 (69.6%) patients at the end of the treatment period. After 24 weeks of telmisartan treatment, LVMI decreased from 151.6 +/- 5.4 to 135.1 +/- 5.9 g/m2. In conclusion, anti-hypertensive treatment with telmisartan for 24 weeks produced significant reductions in blood pressure and regression of LVH, as assessed by LVMI, in patients with hypertension and LVH.
No takes yet. Share an insight, caveat, or question.
Ivanova et al. (2005) studied Mild-to-moderate hypertension and left ventricular hypertrophy (n=24). Telmisartan was evaluated on Target blood pressure levels (SBP/DBP < 140/90 mm Hg). Once-daily telmisartan 40- for 24 weeks achieved target blood pressure in 69.6% of patients and reduced left ventricular mass index from 151.6 to 135.1 g/m2.
Synapse has enriched 10 related papers. Consider them for comparative context: